We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Medincell SA | EU:MEDCL | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.72 | 4.75% | 15.88 | 15.90 | 15.96 | 16.00 | 15.08 | 15.30 | 69,243 | 10:59:36 |
From Nov 2023 to May 2024
Regulatory News:
MedinCell (Paris:MEDCL):
Event
Date*
Annual results 2023-2024 (April 2023-March 2024)
Tuesday, June 25, 2024
General Meeting
Thursday, September 12, 2024
Half-Year results 2024-2025 (April-September 2024)
Tuesday, December 10, 2024
*subject to modification. Publication after financial markets close.
About MedinCell
MedinCell is a clinical- and commercial-stage biopharmaceutical company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine already known and used active ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY™ (BEPO technology is licensed to Teva under the name SteadyTeq™).
We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, MedinCell currently employs more than 140 people representing more than 25 different nationalities.
UZEDY™ and SteadyTeq™ are trademarks of Teva Pharmaceuticals
www.medincell.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201010763/en/
David Heuzé - Head of Communications david.heuze@medincell.com / +33 (0)6 83 25 21 86
Media Relations Nicolas Mérigeau medincell@newcap.eu / +33 (0)1 44 71 94 94
Investor Relations France Louis-Victor Delouvrier/Alban Dufumier medincell@newcap.eu / +33 (0)1 44 71 94 94
Head of US Financial Strategy & IR Grace Kim grace.kim@medincell.com / +1 (646) 991-4023
1 Year Medincell Chart |
1 Month Medincell Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
